Overview of Temovate E Cream

Property	Description
Active Ingredient	Clobetasol Propionate
Form	Topical Cream (Emollient Base)
Pharmacological Class	Super-High Potency Topical Corticosteroid
Common Use	Short-term treatment of moderate to severe skin conditions
Prescription Status	Prescription-only (Rx)

Temovate E Cream is a prescription-only medication used topically for the short-term treatment of certain acute and chronic skin disorders. Its primary active ingredient is clobetasol propionate, present at a 0.05% concentration. This medication is clinically recognized as a super-high potency agent, making it among the most powerful topical corticosteroids available for dermatological use. Clobetasol belongs to the glucocorticoid class, characterized by its potent anti-inflammatory and vasoconstrictive actions.

A key differentiator of this product is the “E” in its name, which denotes its unique emollient base. This base includes ingredients specifically designed to moisturize and soften the dry, scaling, or thickened skin often associated with challenging inflammatory conditions like severe psoriasis or chronic eczema. This formulation feature provides added symptomatic relief beyond the primary action of the steroid.

The use of super-potent corticosteroids is typically reserved for areas of thick skin, severe inflammation, or conditions that have proven resistant to weaker steroid treatments. Due to its strength, Temovate E Cream is prescribed only for short-term use, generally limited to two consecutive weeks. This restriction is a standard protocol for minimizing potential systemic absorption and local side effects associated with potent topical steroids.

Regulatory References

What side effects are possible with Temovate E Cream?

Possible Side Effects and Safety Information

The official safety profile for Temovate E Cream, a super-high potency topical corticosteroid, is structured around the potential for both local and systemic adverse effects. The most commonly reported reactions occur at the application site and include burning, stinging, pruritus (itching), and skin irritation.

Adverse Reaction Classifications

System-Organ Class	Examples of Documented Reactions
Skin and subcutaneous tissue disorders	Skin atrophy (thinning), striae (stretch marks), dryness, telangiectasia (spider veins), folliculitis, hypopigmentation.
Endocrine disorders	Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome.
Metabolism and nutrition disorders	Hyperglycemia (increased blood sugar), glucosuria.

Serious Adverse Reactions and Risk Factors

Serious adverse reactions primarily relate to systemic absorption, which can lead to HPA-axis suppression and Cushing’s syndrome manifestations. The official labeling emphasizes that some local effects, notably severe skin atrophy and striae, may become irreversible.

Safety constraints and risk factors are explicitly stated in the regulatory documents:

Duration: Treatment is generally limited to short courses (e.g., two consecutive weeks) to mitigate systemic risk and local damage.
Pediatrics: Children are at a significantly greater risk of systemic toxicity due to a higher surface area-to-body mass ratio.
Avoidance: Use is restricted on the face, groin, and axillae, and under occlusive dressings, as these conditions significantly increase the rate of absorption.

Overdose and Emergency Response

Overdose and When to Seek Help

The risk of acute overdose with Temovate E Cream (clobetasol propionate) is considered unlikely. However, chronic overuse, prolonged use, or application over large surface areas can lead to systemic toxicity due to increased absorption of the potent corticosteroid.

Documented Overdose Manifestations

Systemic toxicity is officially documented in regulatory sources as an extension of the corticosteroid's effects, primarily involving the Hypothalamic-Pituitary-Adrenal (HPA) axis and metabolic functions.

Classification	Documented Manifestations
HPA Axis Effects	Reversible HPA axis suppression, Clinical Glucocorticosteroid Insufficiency
Metabolic/Endocrine Signs	Hypercortisolism (Cushing's syndrome), Hyperglycemia, Glucosuria

Official Emergency Actions and Population Notes

Official labeling addresses when to seek urgent medical attention and notes specific population risks:

Pediatric Risk: Children are more susceptible to systemic toxicity and HPA axis suppression due to their larger skin surface area-to-body mass ratio.
Accidental Ingestion: For accidental swallowing, it is advised to immediately contact a Poison Control Center or Emergency Services if the person has collapsed or is having difficulty breathing.
Management: If systemic toxicity is confirmed, the product should be gradually withdrawn or substituted with a less potent corticosteroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids as treatment.

Monitoring for HPA axis suppression using clinical tests is required periodically for patients at risk of systemic absorption.

Therapeutic Uses of Temovate E Cream

What Temovate E Cream Treats: Main Uses and Benefits

The medication is classified as a topical corticosteroid, which helps address symptoms related to inflammatory or irritative states of the skin. Its primary role may be part of symptomatic management in conditions characterized by periods of heightened symptoms. The medication is applied in addressing the symptoms related to inflammatory or irritative states and physical discomfort associated with corticosteroid-responsive dermatoses.

The cream is considered relevant in situations involving conditions like plaque-type psoriasis and other conditions associated with acute or disruptive episodes. It is relevant for easing symptoms that become more disruptive during flare-ups, such as redness, swelling, itching (pruritus), and inflammation. It provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases. This may assist with maintaining functional stability during episodes of heightened discomfort.

Quick Fact: Support for Inflammation and Itching

Regulatory References

DailyMed (NIH) Clobetasol Propionate Label

Eligibility and Restrictions for Use

Eligibility for Temovate E Cream Use

Official regulatory documents define strict criteria for the appropriate use of this super-high potency topical corticosteroid. The medication is contraindicated and must not be used by patients with a history of hypersensitivity to clobetasol propionate or any component of the cream. Use is also prohibited for the treatment of rosacea and perioral dermatitis, or other specific conditions like acne vulgaris or untreated cutaneous infections.

Age and Anatomic Restrictions

Use of the cream is generally not recommended in pediatric patients under 12 years of age due to an increased risk of systemic absorption and HPA axis suppression. Safety and effectiveness are not established in children under this age. Furthermore, its application is prohibited on the face, groin, or axillae (underarms), as these areas are more susceptible to local side effects.

Pregnancy and Conditional Use

For pregnant patients, the medication is categorized as Pregnancy Category C, meaning use is permitted only if the potential benefit justifies the potential risk to the fetus. It is unknown if the drug is excreted in human milk, and caution is advised for nursing women. Use is also cautioned in patients with hepatic (liver) impairment due to the potential for delayed elimination and increased systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Although Temovate E Cream (clobetasol propionate) is applied topically, the active ingredient can be absorbed through the skin, especially when used over large areas, for prolonged periods, or with occlusive dressings. This absorption can lead to systemic side effects and drug interactions.

Drugs that May Increase Temovate E Levels

Some medicines can slow the breakdown of clobetasol in the body, potentially increasing its concentration and the risk of systemic side effects, such as HPA axis suppression or Cushing's syndrome. You should inform your healthcare provider if you are taking:

Ritonavir: A medication often used to treat HIV infection.
Itraconazole: An antifungal medication.
Other strong CYP3A4 inhibitors (a type of enzyme inhibitor).

Other Corticosteroids

Using other topical or oral corticosteroid medicines at the same time as Temovate E Cream can significantly increase your risk of systemic corticosteroid side effects. Combining these products may lead to dangerous levels of steroids in the body.

Interaction Type	Examples of Affected Products
Increased Risk of Side Effects	Other prescription or over-the-counter topical steroid creams, ointments, or lotions. Oral steroids (e.g., prednisone).

Vaccines and Immunological Agents

Since high-potency corticosteroids can affect the immune system, their use may interfere with the effectiveness of some vaccines or increase the risk of infection when combined with other immunosuppressive agents. Always discuss your full medication and vaccination history with your doctor.

Mechanism of Action

Temovate E Cream contains clobetasol propionate, a high-potency synthetic corticosteroid. Its mechanism begins upon passive diffusion across the cell membrane, binding to and activating intracellular glucocorticoid receptors (GR) in the cytoplasm of target cells.

This binding event induces a conformational change in the GR complex, allowing its translocation into the cell nucleus. Inside the nucleus, the activated receptor complex acts as a transcription factor, binding to specific glucocorticoid response elements (GREs) on the DNA. This action regulates gene expression, primarily by increasing the transcription of anti-inflammatory proteins, such as lipocortin-1 (annexin-A1). Lipocortin-1 inhibits the enzyme phospholipase A2 ( PLA2), preventing the release of arachidonic acid from membrane phospholipids. The suppression of arachidonic acid synthesis thereby limits the production of pro-inflammatory mediators, including prostaglandins and leukotrienes, via the cyclooxygenase and lipoxygenase pathways. Furthermore, clobetasol modulates the expression of various chemokines and adhesion molecules and suppresses the proliferation of T-lymphocytes, leading to an overall reduction in capillary permeability and cellular infiltration at the application site.

Dosage and Administration Information

How to Use Temovate E Cream

This section describes the administration guidelines for Temovate E Cream (clobetasol propionate 0.05% in an emollient base).

Administration Scope

Property	Instruction
Route of administration	Topical (Dermal application)
Dosing schedule	Apply a thin layer to the affected area(s). The total amount used must not exceed 50 grams per week.
Frequency pattern	Twice daily application.
Course Duration	Treatment is strictly limited to 14 consecutive days.
Age-group restriction	Use in pediatric patients under 12 years of age is generally not established or recommended.
Special procedural conditions	Application must cease immediately when control of the symptoms is achieved. The cream is generally restricted from use on the face, groin, or armpits.

Resulting Procedural Structure

The protocol requires the application of a thin layer of the cream to the affected skin area(s) through the topical route, typically on a twice daily schedule. The key usage constraints enforce a strict time limit on treatment, mandating that the application does not exceed a maximum of 14 consecutive days of use. This short-term usage pattern is also restricted by a maximum weekly amount of 50 grams of cream. Furthermore, the instructions specify that application should be discontinued when symptoms are controlled and that the use of occlusive dressings is generally advised against. These instructions define the standardized approach to using the medicine.

Recent Clinical Evidence

Temovate E Cream: Recent Clinical Evidence

Clinical research has focused on the investigation of clobetasol propionate, the active ingredient in Temovate E Cream, primarily across various inflammatory and immune-mediated dermatological conditions. Studies are designed to evaluate its effects compared to other topical agents and placebo, particularly in conditions where potent corticosteroid activity is warranted.

Psoriasis and Eczema Studies

Trials exploring psoriasis commonly assess efficacy by tracking the Psoriasis Area and Severity Index (PASI) score. Research has shown that clobetasol propionate is used as a standard comparator in topical treatment trials due to its known activity profile. For eczema (atopic dermatitis), studies monitor outcome measures such as the Eczema Area and Severity Index (EASI) and overall quality-of-life scores, often comparing the cream formulation against other vehicles or active treatments.

Study Design and Administration

Most clinical studies are structured as randomized, controlled trials (RCTs). These studies define specific treatment periods, frequently ranging from two to four weeks, to determine the effect on the investigated condition. Research reports primarily document changes in symptom severity, reduction in signs of inflammation (e.g., erythema and induration), and local tolerability at the application site.

Formulation and Absorption

The Emollient (E) cream formulation has been specifically evaluated for its ability to enhance the absorption of clobetasol propionate through the skin barrier, compared to standard creams or ointments. Research aims to characterize the impact of this vehicle on the delivery of the active agent, which may influence its overall profile when studied in clinical settings.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Temovate E Cream (FAQ)

Q: Is Temovate E Cream the same as clobetasol propionate cream?

Temovate E Cream is the brand name for a topical medication that uses clobetasol propionate 0.05% as its active ingredient. This means that both products contain the same principal medicinal component. However, the inactive ingredients and the specific cream base may differ between the brand-name product and generic versions.

Q: What is the difference between Temovate Cream and Temovate E Cream?

The 'E' in Temovate E Cream stands for emollient base. This indicates that the cream contains a specialized formula of inactive ingredients designed to moisturize and soften the skin, which may be beneficial for dry skin conditions. The standard Temovate Cream uses a different base formulation, but both products contain the same active ingredient.

Q: Does using Temovate E Cream for a long time change how it works?

Official regulatory documents place a strict limit on the duration of treatment, typically to 14 consecutive days. This is done to help minimize the risk of serious systemic effects, such as the suppression of the hypothalamic-pituitary-adrenal (HPA) axis. These risks are associated with the prolonged use of high-potency topical corticosteroids.

Q: Can Temovate E Cream be used on large areas of the body?

Official instructions caution against using Temovate E Cream over large areas of the body. Regulatory constraints limit the total amount used to 50 grams per week. Applying the cream to extensive areas can lead to increased absorption of the active ingredient through the skin, raising the risk of systemic side effects.

Q: Are there published studies about the long-term use of Temovate E Cream?

The regulatory approval of this medicine is based on clinical trials that evaluated its effects over short-term treatment periods, typically ranging from two to four weeks. Long-term use is not typically supported by the specific data submitted for product approval, which is why treatment duration is officially limited.

Q: What type of conditions are generally not responsive to Temovate E Cream?

Official labeling prohibits the use of the cream for certain conditions. These prohibited uses include rosacea, perioral dermatitis, acne vulgaris, and untreated cutaneous infections. This medicine is intended only for corticosteroid-responsive skin disorders.

Q: How long does it typically take to see results from Temovate E Cream?

Official patient information indicates that if no improvement is seen within two consecutive weeks of starting treatment, a reevaluation of the diagnosis may be necessary. This two-week period is a timeframe described in regulatory documents for healthcare providers to reassess the diagnosis if improvement has not been observed.

Q: If I miss a dose, what should I do?

Regulatory documents describe the protocol for a missed application as applying it when remembered, unless it is close to the time of the next scheduled application, in which case the prior application is typically omitted. This approach is intended to prevent excessive or repeated applications.

Q: What happens if I accidentally swallow a small amount of Temovate E Cream?

This product is strictly for use on the skin. Official patient guidance warns that this medicine may be harmful if swallowed. If accidental ingestion occurs, advice should be sought from a poison control center or emergency services.

Q: Does Temovate E Cream have an effect on the eyes or vision?

Official labeling states that use in or near the eyes is prohibited. Safety reports associated with topical clobetasol have included documented adverse reactions related to the eyes, such as irritation, eye pain, and blurred vision.

Q: Do older adults (seniors) need to take special precautions with Temovate E Cream?

Official product labeling does not typically recommend a different dosage or specific precautions solely based on advanced age. Dosage and precautions for adults who are elderly are generally the same as those for the general adult population.

Q: Is there a generic version of Temovate E Cream?

Yes, the active ingredient, clobetasol propionate, is widely available as a generic medication. Generic versions are often available in various topical forms, including creams and ointments.

Q: Is it okay to use Temovate E Cream near mucous membranes?

Official instructions specify that the cream is not intended for use on or near mucous membranes. This includes areas such as the eyes, nose, mouth, and the vaginal area, as these sites are highly susceptible to increased absorption and adverse effects.

Q: What is the evidence regarding Temovate E Cream for lichen planus?

The active ingredient is officially indicated for the relief of inflammatory and itchy manifestations of corticosteroid-responsive dermatoses. This broad category is described as being responsive to the potent anti-inflammatory action of the medication. The official indication covers conditions such as lichen planus.

Q: Will Temovate E Cream help with itchiness caused by poison ivy?

The medicine is officially indicated for treating the inflammatory and itchy manifestations of corticosteroid-responsive dermatoses. Poison ivy is not specifically named in the official indication.

Q: What should I do if my skin condition gets worse while using Temovate E Cream?

Official patient information states that if the condition being treated lasts or appears to get worse after two weeks of using the cream, a healthcare provider should be consulted. Worsening symptoms may indicate the need for a re-evaluation of the diagnosis.

Q: Does Temovate E Cream make skin more sensitive to the sun?

Some safety studies and reports associated with the use of high-potency topical corticosteroids have noted potential risks, including increased photosensitivity (sensitivity to sunlight) at the application site. This effect is a documented potential risk associated with the use of high-potency corticosteroids.

Q: What are the ingredients besides the active medication in Temovate E Cream?

The official regulatory package insert and Patient Information Leaflet contain a complete list of inactive ingredients, also known as excipients. These ingredients are included to create the cream’s base, aid stability, and help with absorption.

Q: Does Temovate E Cream contain any parabens?

The official regulatory labeling is required to list all ingredients, including preservatives. The full and specific list of inactive ingredients can be found in the product's official package insert, which can be checked to determine if the formula contains substances like parabens.

Q: Does Temovate E Cream have an expiration date?

Yes. As with all approved prescription medicines, the tube of Temovate E Cream is required by regulatory authorities to display an expiration date printed by the manufacturer. This date helps ensure the medicine's quality and stability when stored correctly.

How should Temovate E Cream be stored and disposed of?

How to Store and Dispose of Temovate E Cream

Storage and disposal instructions for Temovate E Cream (clobetasol propionate 0.05%) are defined by regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Temovate E Cream must be stored at Controlled Room Temperature (CRT), which is typically 20 C to 25 C (68 F to 77 F). The cream must not be refrigerated and must not be frozen. It must be kept in its original container, which should be tightly closed when not in use, and kept out of the sight and reach of children.

Disposal Guidelines

Disposal instructions advise against flushing the cream down a toilet or pouring it into a drain. Unused or expired medication should be disposed of by following official drug take-back programs or local waste management guidelines.

Temovate E Cream